

**BIBLIOGRAPHY**  
**ROBERT YARCHOAN, M.D.**

**Articles and Chapters**

1. Popkin MK, Moldow CR, Hall RDH, Branda FR, **Yarchoan R**. Psychiatric aspects of allogeneic bone marrow transplantation for aplastic anemia. *Dis Nerv Syst* 1977;38:925-7.
2. Davies SF, Gormus BD, **Yarchoan R**, Kaplan ME. Cryptococcal meningitis with false-positive serology in the CSF. *JAMA* 1978;239:2369-70.
3. **Yarchoan R**, Davies SF, Fried J, Manowald ML. Isolated *Candida parapsilosis* arthritis in a heroin addict. *J Rheumatol* 1979;6:447-50.
4. Richman LK, Graeff AS, **Yarchoan R**, Strober W. Simultaneous induction of antigen-specific IgA helper T cells and IgG suppressor cells in the murine Peyer's patch following protein feeding. *J Immunol* 1981;126:2079-83.
5. Murphy BR, Phalan MA, Nelson DL, **Yarchoan R**, Tierney EL, Alling DW, Chanock RM. A hemagglutinin-specific enzyme-linked immuno-sorbent assay (ELISA) for antibodies to influenza A and B viruses. *J Clin Microbiol* 1981;13:554-60.
6. **Yarchoan R**, Murphy BR, Strober W, Clements ML, Nelson DL. *In vitro* production of anti-influenza virus antibody following intra-nasal inoculation with cold-adapted virus. *J Immunol* 1981;127:158-63.
7. **Yarchoan R**, Murphy BR, Strober W, Biddison WE, Blaese RM, Nelson DL. Specific anti-influenza virus antibody production *in vitro* by human peripheral blood mononuclear cells. In: Resch K, Kirchner, eds. *Mechanisms of Leukocyte Activation. Proceedings of the 14th Leukocyte Culture Conference*. New York: Elsevier/North Holland, 1981;677-9.
8. **Yarchoan R**, Murphy BR, Strober W, Schneider HS, Nelson DL. Specific anti-influenza virus antibody production *in vitro* by human peripheral blood mononuclear cells. *J Immunol* 1982;2:118-25.
9. **Yarchoan R**, Biddison WE, Schneider HS, Nelson DL. Human T-cell subset requirements for the production of specific anti-influenza virus antibody *in vitro*. *J Clin Immunol* 1982;2:118-25.
10. **Yarchoan R**, Tosato G, Blaese RM, Simon RM, Nelson DL. Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production by human B cells. *J Exp Med* 1983;157:1-14.
11. **Yarchoan R**, Schneider HS, Wray BB, Nelson DL. Specific anti-influenza virus antibody production *in vitro* by lymphocytes from a subset of patients with hypogammaglobulinemia. *J Clin Invest* 1983;71:1720-7.
12. **Yarchoan R**, Nelson DL. A study of the functional capabilities of human neonatal lymphocytes for *in vitro* specific antibody production. *J Immunol* 1983;131:1222-8.

**Robert Yarchoan, M.D.**

**Bibliography**

13. **Yarchoan R**, Nelson DL. Specificity of *in vitro* anti-influenza virus antibody production by human lymphocytes: analysis of original antigenic sin by limiting dilution cultures. *J Immunol* 1984;132:928-35.
14. **Yarchoan R**, Engler RJM, Barrow LA, Kurman CC, Nelson DL. Antigen-stimulated human B cell clones are committed to the production of a single class of antibody *in vitro*. *J Immunol* 1984;132:2696-9.
15. Tosato G, Steinberg AD, **Yarchoan R**, Heilman CA, Pike SA, Blaese RM. Abnormally elevated frequency of Epstein Barr-virus infected B cells in the blood of patients with rheumatoid arthritis. *J Clin Invest* 1984;73:1789-95.
16. **Yarchoan R**, Kurman CC, Nelson DL. Nature of the cellular abnormalities contributing to deficient *in vitro* specific antibody production in patients with ataxia-telangiectasia (AT). In: Griscelli C, Vossen J, eds. *Progress in Immunodeficiency Research and Therapy I*. Amsterdam: Excerpta Medica, 1984;169-70.
17. Mitsuya H, Popovic M, **Yarchoan R**, Matsushita S, Gallo RC, Broder S. Suramin protection of T cells *in vitro* against infectivity and cytopathic effect of HTLV-III. *Science* 1984;226(4671):172-174.
18. **Yarchoan R**, Kurman CC, Nelson DL. Defective specific anti-influenza virus antibody production by lymphocytes from patients with ataxia-telangiectasia. In: Gatti RA, Swift M, eds. *Ataxia-telangiectasia: Genetics, Neuropathology, and Immunology of a Degenerative Disease of Childhood. Kroc Foundation Series, Volume 19*. New York: Alan R. Liss, 1985;315-29.
19. Tosato G, Blaese RM, **Yarchoan R**. Relationship between immunoglobulin production and immortalization by Epstein-Barr virus. *J Immunol* 1985;135:959-964.
20. **Yarchoan R**, Mitsuya H, Matsushita S, Broder S. Implications of the discovery of HTLV-III for the treatment of AIDS. *Cancer Res* 1985;45(9 suppl):4685s-8s.
21. Weiler JM, Rinderknecht SB, Sharath MD, **Yarchoan R**. Human secondary immune response induced by influenza virus in a serum-free tissue culture system. *J Immunol Methods* 1985;82:333-9.
22. Broder S, **Yarchoan R**, Collins JM, Lane HC, Markham PD, Klecker RW, Redfield RR, Mitsuya H, Hoth DF, Gelmann E, Groopman JE, Resnick L, Gallo RC, Myers CE, Fauci AS. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication *in vivo*. *Lancet* 1985;(8456):627-30.
23. Rubin LA, Kurman CC, Fritz ME, **Yarchoan R**, Nelson DL. Identification and characterization of a released form of the IL-2 receptor. In: Oppenheim JJ, Jacobs DM, eds. *Leukocytes and Host Defense*. New York: Alan R. Liss, 1985;95-102.
24. **Yarchoan R**, Barrow LA, Kurman C, Strober W, Nelson DL. Human peripheral blood mononuclear cells produce IgA anti-influenza virus antibody in a secondary *in vitro* antibody response. *J Immunol* 1985;135:1033-9.
25. Mitsuya H, Matsushita S, **Yarchoan R**, Broder S. Protection of T cells against infectivity and cytopathic effect of HTLV-III *in vitro*. In: Miwa M, Sugano H, Sugimura T, Weiss RA, eds. *Princess Takamatsu Symposium. Retroviruses in Human Lymphoma/leukemia*. Tokyo: Japan Science Soc Press, 1985;277-88.

**Robert Yarchoan, M.D.**

**Bibliography**

26. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, **Yarchoan R**, Nelson DL. Soluble interleukin 2 receptors are released from activated human lymphoid cells *in vitro*. *J Immunol* 1985;135:3172-7.
27. Collins JM, Klecker RW Jr, **Yarchoan R**, Lane HC, Fauci AS, Redfield RR, Broder S, Myers CE. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. *J Clin Pharmacol* 1986;26(1):22-6.
28. **Yarchoan R**, Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, Durack DT, Gelmann E, Nusinoff Lehrman S, Blum RM, Barry DW, Shearer GM, Fishl MA, Mitsuya H, Gallo RC, Collins JM, Bolognesi DP, Myers CE, Broder S. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. *Lancet* 1986; 327 (8481):575-80.
29. Tosato G, Marti GE, **Yarchoan R**, Heilman CA, Wang F, Pike SE, Korsmeyer SJ, Siminovitch K. Epstein-Barr virus immortalization of normal cells of B cell lineage with non-productive, rearranged immunoglobulin genes. *J Immunol* 1986;137:2037-42.
30. **Yarchoan R**, Guo H-G, Reitz M Jr, Maluish A, Mitsuya H, Broder S. Alterations in cytotoxic and helper T cell function after infection of T cell clones with human T cell leukemia virus, type I. *J Clin Invest* 1986;77(5):1466-73.
31. **Yarchoan R**, Redfield RR, Broder S. Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus. *J Clin Invest* 1986;78(2):439-47.
32. Mitsuya H, **Yarchoan R**, Broder S. 2',3'-dideoxynucleoside analogues: development of anti-viral therapy for HTLV-III/LAV associated diseases. *Trop Med* 1986;28(suppl):119-26.
33. **Yarchoan R**, Berg G, Brouwers P, Fischl MA, Spitzer AR, Wichman A, Grafman J, Thomas RV, Safai B, Brunetti A, Perno CF, Schmidt PJ, Larson SM, Myers CE, Broder S. Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine. *Lancet* 1987;1:132-5.
34. **Yarchoan R**, Broder S. Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. *N Engl J Med* 1987;316(9):557-64. [**Yarchoan R**, Broder S. Antiretroviral therapy for AIDS (letter). *N Eng J Med* 1987;317:629-30.]
35. Klecker RW Jr, Collins JM, **Yarchoan R**, Thomas R, Jenkins JF, Broder S, Myers CE. Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. *Clin Pharmacol Ther* 1987;41(4):407-12.
36. **Yarchoan R**, Broder S. Strategies for the pharmacological intervention against HTLV-III/LAV. In: Broder S, ed. *AIDS: Modern Concepts and Therapeutic Challenges*. New York: Marcel Dekker, 1987;335-60.
37. **Yarchoan R**, Broder S. Preliminary results on the use of dideoxynucleosides in the therapy of AIDS. In: Chanock RM, Lerner RA, Brown F, Ginsberg H, eds. *Vaccines 87. Modern Approaches to New Vaccines. Prevention of AIDS and*

**Robert Yarchoan, M.D.**

**Bibliography**

- Other Viral, Bacterial, and Parasitic Diseases*. New York: Cold Spring Harbor Laboratory, 1987;214-24.
38. **Yarchoan R**, Masur H, Broder S. Therapy of acquired immunodeficiency syndrome. In: Pinedo HM, Longo DL, Chabner BA, eds. *Cancer Chemotherapy and Biological Response Modifiers Annual 9*. Amsterdam: Elsevier Science Publishers, 1987;200-25.
  39. **Yarchoan R**, Broder S. Progress in the development of antiviral therapy for HTLV-III-associated diseases. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. *Important Advances in Oncology 1987*. Philadelphia: JB Lippincott Company, 1987;293-311.
  40. **Yarchoan R**, Thomas R, Fischl MA, Grafman J, Wichman A, Dalakas M, Jacobsen FK, McAtee N, Perno CF, Safai B, Klecker RW, Collins JM, Berg G, Brunetti A, Schmidt PJ, Brouwers P, Spitzer AR, Larson SM, Myers CE, Broder S. Treatment of human immunodeficiency virus-associated neurological disease with 3'-azido-2',3'-dideoxythymidine. In: Bolognesi D, ed. *Human retroviruses, Cancer, and AIDS: Approaches to Prevention and Therapy*. UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 71. New York: Alan R. Liss, 1988;393-406.
  41. **Yarchoan R**, Perno CF, Thomas RV, Klecker RW, Allain J-P, Wills RJ, McAtee N, Fischl MA, Dubinsky R, McNeely MC, Mitsuya H, Pluda JM, Lawley TJ, Leuther M, Safai B, Collins JM, Myers CE, Broder S. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). *Lancet* 1988;1:76-81. [Dubinsky RM, Dalakas M, **Yarchoan R**, Broder S. Follow-up of neuropathy from 2',3'-dideoxycytidine (letter). *Lancet* 1988;1:832.]
  42. **Yarchoan R**, Thomas RV, Grafman J, Wichman A, Dalakas M, McAtee N, Berg G, Fischl M, Perno CF, Klecker RW, Buchbinder A, Tay S, Larson SM, Myers CE, Broder S. Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease. *Ann Neurol* 1988;23(suppl):S82-S87.
  43. Dalakas MC, **Yarchoan R**, Spitzer R, Wilder G, Sever JL. Treatment of HIV-related polyneuropathy with 3'-azido-2',3'-dideoxythymidine (AZT): a case report. *Ann Neurol* 1988;23(suppl);S92-S93.
  44. Surbone A, **Yarchoan R**, McAtee N, Blum MR, Maha M, Allain J-P, Thomas RV, Mitsuya H, Nusinoff-Lehrman S, Leuther M, Pluda JM, Jacobsen FK, Kessler HA, Myers CE, Broder S. Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3'-azido-2',3'-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. *Ann Intern Med* 1988;108:534-40.
  45. Mann DL, Murray C, **Yarchoan R**, Blattner WA, Goedert JJ. HLA antigen frequencies in HIV-1 seropositive disease-free individuals and patients with AIDS. *J AIDS* 1988;1:13-7.
  46. **Yarchoan R**, Strober W, Murphy BR, Nelson DL. *In vitro* production IgA antibody by human lymphocytes. In: Strober W, Lamm MD, McGee JR, James SP, eds. *Mucosal Immunity and Infections at Mucosal Surfaces*. New York: Oxford University Press, 1988;94-103.

## Robert Yarchoan, M.D.

### Bibliography

47. Perno C-F, **Yarchoan R**, Cooney DA, Hartman NR, Gartner S, Popovic M, Hao Z, Gerrard TL, Wilson YA, Johns DG, Broder S. Inhibition of human immunodeficiency virus (HIV-1/HTLV-III<sub>Ba-L</sub>) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. *J Exp Med* 1988;168(3):1111-25.
48. **Yarchoan R**, Mitsuya H, Broder S. AIDS therapies. *Sci Am* 1988;256(10):110-9.
49. Pizzo PA, Eddy J, Falloon J, Balis FM, Murphy RF, Moss H, Wolters P, Brouwers P, Jarosinski P, Rubin M, Broder S, **Yarchoan R**, Brunetti A, Maha M, Nusinoff-Lehrman S, Poplack DG. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. *N Engl J Med* 1988;319(14):889-96.
50. **Yarchoan R**, Mitsuya H, Broder S. Therapeutic strategies in the treatment of AIDS. In: Allen RC, ed. *Annual Reports in Medicinal Chemistry. Volume 23*. San Diego: Academic Press, 1988;253-63.
51. **Yarchoan R**, Pluda JM. Clinical aspects of infection with AIDS retrovirus: acute HIV infection, persistent generalized lymphadenopathy, and AIDS-related complex. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. *AIDS, Second Edition. Etiology, Diagnosis, Treatment, and Prevention*. Philadelphia: JB Lippincott Company, 1988;107-20.
52. **Yarchoan R**, Broder S. Pharmacologic treatment of HIV infection. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. *AIDS, Second edition. Etiology, Diagnosis, Treatment, and Prevention*. Philadelphia: JB Lippincott Company, 1988;277-93.
53. **Yarchoan R**, Masur H, Broder S. AIDS and related disorders. In: Pinedo HM, Longo DL, Chabner BA, eds. *Cancer Chemotherapy and Biological Response Modifiers Annual 10*. Amsterdam: Elsevier Science Publishers, 1988;182-209.
54. Klecker RW Jr, Collins JM, **Yarchoan R**, Thomas R, McAtee N, Broder S, Myers CE. Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders. *J Clin Pharmacol* 1988;28:837-42.
55. **Yarchoan R**, Broder S. Anti-retroviral therapy of AIDS and related disorders: general principles and specific development of dideoxynucleosides. *Pharmacol Ther* 1989;40:329-48.
56. Perno C-F, **Yarchoan R**, Cooney DA, Hartman NR, Webb DSA, Hao Z, Mitsuya H, Johns DG, Broder S. Replication of human immunodeficiency virus in monocytes. Granulocyte-macrophage colony stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'azido-2',3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. *J Exp Med* 1989;169:933-51.
57. Ranki A, Mattinen S, **Yarchoan R**, Broder S, Ghayeb J, Lähdevirta J, Krohn K. T-cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners. *AIDS* 1989;3:63-9.
58. **Yarchoan R**, Broder S. Pharmacologic principles for the treatment of HIV infection. In: Cali R, Nisticì G, eds. *Antiviral drugs. Basic and Therapeutic Aspects*. Rome-Milan: Pythagora Press, 1989;11-33.

**Robert Yarchoan, M.D.**

**Bibliography**

59. Brunetti A, Berg G, Di Chiro G, Cohen RM, **Yarchoan R**, Pizzo PA, Broder S, Eddy J, Fulham MJ, Finn RD, Larson SM. Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine): a PET-FDG study. *J Nucl Med* 1989;30(5):581-90.
60. **Yarchoan R**, Mitsuya H, Thomas RV, Pluda JM, Hartman NR, Perno C-F, Marczyk KS, Allain J-P, Johns DG, Broder S. *In vivo* activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. *Science* 1989;245:412-15.
61. Masur H, Ognibene FP, **Yarchoan R**, Shelhamer JH, Baird BF, Travis W, Suffredini AF, Deyton L, Kovacs JA, Falloon J, Davey R, Polis M, Metcalf J, Baseler M, Wesley R, Gill VJ, Fauci AS, Lane HC. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. *Ann Intern Med* 1989;111(3):223-31.
62. **Yarchoan R**, Broder S. Immunology of HIV infection. In: Paul WE, ed. *Fundamental immunology. Second edition*. New York: Raven Press, 1989;1059-79.
63. **Yarchoan R**, Mitsuya H, Broder S. Clinical and basic advances in the antiretroviral therapy of human immunodeficiency virus infection. *Am J Med* 1989;87:191-200.
64. **Yarchoan R**, Mitsuya H, Myers CE, Broder S. Antiretroviral therapy of HIV infection: clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (AZT) and related dideoxynucleosides. *N Engl J Med* 1989;321(11):726-38.
65. Dubinsky RM, **Yarchoan R**, Dalakas M, Broder S. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2',3'-dideoxycytidine (ddC). *Muscle Nerve* 1989;12:856-60.
66. de Miranda P, Good SS, **Yarchoan R**, Thomas RV, Blum MR, Myers CE, Broder S. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. *Clin Pharmacol Ther* 1989;46:494-500.
67. McNeely MC, **Yarchoan R**, Broder S, Lawley TJ. Dermatologic complications associated with administration of 2',3'-dideoxycytidine in patients with human immunodeficiency virus infection. *J Am Acad Dermatol* 1989;21:1213-7.
68. Lisker-Melman M, Pittaluga S, Pluda JM, Kleiner DE, Thompson P, Martin P, **Yarchoan R**, Di Bisceglie AM. Primary lymphoma of the liver in a patient with acquired immune deficiency syndrome and chronic hepatitis B. *Am J Gastroenterol* 1989;84(11):1445-8.
69. **Yarchoan R**, Broder S. The use of antiretroviral therapy for the treatment of AIDS and related disorders. In: Rapoza N, ed. *HIV Infection and Disease*. Monographs for physicians and other health care workers. Chicago: American Medical Association, 1989;87-101.
70. **Yarchoan R**, Pluda JM, Perno CF, Mitsuya H, Thomas RV, Marczyk K, Broder S. Initial clinical experience with Dideoxynucleosides as single agents and in combination therapy. *Ann NY Acad Sci* 1990;616:326-343.
71. Hartman NR, **Yarchoan R**, Pluda JM, Thomas RV, Marczyk KS, Broder S. Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. *Clin Pharmacol Ther*, 1990;47(5):647-54.

**Robert Yarchoan, M.D.**

**Bibliography**

72. Broder S, **Yarchoan R**. Dideoxycytidine: current clinical experience and future prospects. A summary. *Am J Med*, 1990;88(suppl 5B):31S-3S.
73. **Yarchoan R**, Mitsuya H, Pluda JM, Marczyk KS, Thomas RV, Hartman NR, Brouwers P, Perno C-F, Allain J-P, Johns DG, Broder S. The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles. *Rev Infect Dis*, 1990;12(suppl 5):S522-S33.
74. **Yarchoan R**, Pluda JM, Mitsuya H, Broder S. Treatment of acquired immunodeficiency syndrome. In: Pinedo HM, Longo DL, Chabner BA, eds. *Cancer Chemotherapy and Biological Response Modifiers Annual 11*. Amsterdam: Elsevier, 1990;379-415.
75. Mitsuya H, **Yarchoan R**, Hayashi S, Broder S. Antiviral therapy against HIV infection. *J Am Acad Dermatol* 1990;22(6):1282-92.
76. Pluda JM, **Yarchoan R**, Smith PD, McAtee N, Shay LE, Oette D, Maha M, Wahl SM, Myers CE, Broder S. Subcutaneous recombinant GM-CSF used as a single agent and in an alternating regimen with azidothymidine (AZT) in leukopenic patients with severe human immunodeficiency virus (HIV) infection. *Blood*, 1990;76(3):463-72.
77. Pluda JM, **Yarchoan R**, Jaffe ES, Feuerstein IM, Solomon D, Steinberg SM, Wyvill KM, Raubitschek A, Katz D, Broder S. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. *Ann Intern Med* 1990;113(4):276-82.
78. **Yarchoan R**, Mitsuya H, Broder S. Immunologic issues in anti-retroviral therapy. *Immunol Today* 1990;11(9):327-33.
79. **Yarchoan R**, Pluda JM, Thomas RV, Mitsuya H, Brouwers P, Wyvill KM, Hartman N, Johns DG, Broder S. Long term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. *Lancet* 1990;336(8714):526-9.
80. Perno C-F, Cooney DA, Currens MJ, Rocchi G, Johns DG, Broder S, **Yarchoan R**. Ability of anti-HIV agents to inhibit HIV replication in monocyte/macrophages or U937 monocytoid cells under conditions of enhancement by GM-CSF or anti-HIV antibody. *AIDS Res Hum Retroviruses* 1990;6:1051-5.
81. Mitsuya H, **Yarchoan R**, Broder S. Molecular targets for AIDS therapy. *Science* 1990;249:1533-44.
82. Mitsuya H, Hayashi S, **Yarchoan R**, Aoki S, Currens MJ, Matsukura M, Broder S. Strategy of targeted antiretroviral therapy against human immunodeficiency virus (HIV). In: Groopman JE, Chen I, Essex M, Weiss R, eds. *Human Retroviruses. UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 119*. New York: Alan R. Liss, 1990;239-59.
83. **Yarchoan R**. Taking drugs from test tubes to patients, pp 607-12. In: Broder S, moderator. Antiretroviral therapy in AIDS. *Ann Intern Med* 1990;113(8):604-18.
84. Aoki S, **Yarchoan R**, Thomas RV, Pluda JM, Marczyk K, Broder S, Mitsuya H. Quantitative analysis of HIV-1 proviral DNA in peripheral blood mononuclear cells from patients with AIDS or ARC: decrease of proviral DNA content

**Robert Yarchoan, M.D.**

**Bibliography**

- following treatment with 2',3'-dideoxyinosine (ddI). *AIDS Res Hum Retroviruses* 1990;6(11):1331-9.
85. **Yarchoan R**, Mitsuya H, Broder S. Strategies for the combination therapy of HIV infection. *J AIDS* 1990;3(suppl 2):S99-S103.
86. Perno CF, Baseler MW, Broder S, **Yarchoan R**. Infection of monocytes by HIV-1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies. *J Exp Med* 1990;171:1043-56.
87. Pluda JM, **Yarchoan R**, Broder S. The occurrence of opportunistic non-Hodgkin's lymphomas in the setting of infection with the human immunodeficiency virus. *Ann Oncol* 1991;2(suppl 2):191-200. [Pluda JM, **Yarchoan R**, Broder S. HIV-associated non-Hodgkin's lymphomas. [Editorial] *Ann Oncol* 2;248-9:1991.]
88. Gail MH, Pluda JM, Rabkin CS, Biggar RJ, Goedert JJ, Horm J, Sondik EJ, **Yarchoan R**, Broder S. Projections of the incidence of AIDS-related non-Hodgkin's lymphoma. *J Natl Cancer Inst*, 1991; 83(10):695-701.
89. Pluda JM, Broder S, **Yarchoan R**. Therapy of AIDS and AIDS-related tumors. In: Pinedo HM, Longo DL, Chabner BA, eds. *Cancer Chemotherapy and Biological Response Modifiers Annual 12*. Amsterdam: Elsevier; 1991, 395-429.
90. **Yarchoan R**. Measurement of in-vitro specific antibody synthesis. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. *Current Protocols in Immunology*. New York: John Wiley and Sons, 1991:7.15.1-5.
91. Levine SJ, Masur H, Gill VJ, Feuerstein I, Suffredini AF, Brown D, Lane HC, **Yarchoan R**, Shelhamer JH, Ognibene FP. The effect of aerosolized pentamidine prophylaxis on the diagnosis of *Pneumocystis carinii* pneumonia by induced sputum examination in patients infected with the human immunodeficiency virus. *Ann Rev Resp Dis*. 1991, 144: 760-764.
92. **Yarchoan R**, Pluda J, Perno CF, Mitsuya H, Broder S. Anti-retroviral therapy of HIV infection: Current strategies and challenges for the future. *Blood*. 1991; 78(4):859-84.
93. **Yarchoan R**, Venzon DJ, Pluda JM, Lietzau J, Wyvill KM, Tsiatis AA, Steinberg SM, Broder S. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. *Ann Intern Med*. 1991; 115(3): 184-9. [**Yarchoan R**, Tsiatis AA, Broder S. CD4 counts and HIV-related deaths (letter). *Ann Intern Med*. 1992; 116(2):169-170.]
94. Mitsuya H, **Yarchoan R**, Kageyama S, Broder S. Targeted therapy of human immunodeficiency virus-related disease. *FASEB J*. 1991; 5(10);2369-81.
95. National Cancer Institute and Office of the Deputy Director (HIV), Centers for Disease Control (Pluda JM, **Yarchoan R**, Venzon D, Lietzau J, Gail M, Rabkin CS, Goedert JJ, Blattner WA, Karp JE, Broder S.) Non-Hodgkin's lymphoma in severely immunocompromised HIV-infected patients surviving for prolonged periods on antiretroviral therapy - United States. *MMWR*. 1991; 40(34):591-600.
96. Pluda JM, Mitsuya H, **Yarchoan R**. Hematologic effects of AIDS therapies. In: Mitsuyasu RT and Golde DW, eds. Hematologic and oncologic aspects of HIV diseases. *Hematol Oncol Clin North Am* 1991;5:229-248.
97. Hartman NR, **Yarchoan R**, Pluda JM, Thomas RV, Wyvill KM, Flora KP, Broder S, Johns DG. Pharmacokinetics of 2',3'-dideoxyinosine in patients with

## Robert Yarchoan, M.D.

### Bibliography

- severe human immunodeficiency infection. II. The effect of different oral formulations and the presence of other medicines. *Clin Pharm Therapeutics*. 1991;50(3):278-85.
98. McKenzie R, Travis WD, Dolan SA, Pittaluga S, Feuerstein IM, Shelhamer J, **Yarchoan R**, Masur H. The causes of death in patients with HIV infection: a clinical and pathological study with emphasis on the role of pulmonary disease. *Medicine*. 1991;70(5):326-43.
99. Pluda JM, Lietzau J, Tosato G, Venzon D, Birx DL, Broder S, **Yarchoan R**. Development of opportunistic non-Hodgkin's lymphomas in severely immunosuppressed HIV-infected patients receiving long-term antiretroviral therapy. In: Rossi GB, Beth-Giraldo E, Chieco-Bianchi L, Dianzani F, Giraldo G, Verani P, eds. *Science Challenging AIDS*. Basel: Karger; 1992, 196-206.
100. **Yarchoan R**, Broder S. Treatment of AIDS and related disorders. In: Wyngaarden JB, Smith LH Jr, Claude JC, Plum F, eds. *Cecil Textbook of Medicine, Nineteenth Edition*. Philadelphia: WB Saunders, 1992; 1957-1965.
101. **Yarchoan R**, Broder S. Correlations between the *in vitro* and *in vivo* activity of anti-HIV agents: Implications for future drug development. *Enzyme Inhibition*. 1992; 6(1): 99-111.
102. Perno CF, **Yarchoan R**, Balzarini J, Bergamini A, Milanese G, Pauwels R, De Clercq E, Rocchi G, Calio R. Different patterns of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages. *Antiviral Research*. 1992; 17 : 289-304.
103. **Yarchoan R**, Mitsuya H, Broder S. The immunology of HIV infection: Implications for therapy. *AIDS Res Hum Retroviruses*. 1992; 8: 1023-1031.
104. Aoki-Sei S, **Yarchoan R**, Kagayama S, Hoekzema DT, Pluda JM, Wyvill KM, Broder S, Mitsuya H. Plasma HIV-1 viremia in HIV-1 infected individuals assessed by polymerase chain reaction. *AIDS Res Hum Retroviruses*. 1992; 8: 1263-1270.
105. Perno CF, Cooney DA, Gao WY, Hao Z, Johns DG, Foli A, Hartman N, Calio' R, Broder S, **Yarchoan R**. Effects of bone marrow stimulatory cytokines on HIV replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages. *Blood*. 1992; 80: 995-1003.
106. Pluda JM, Broder S, **Yarchoan R**. Therapy of AIDS and AIDS-related tumors. In: Pinedo HM, Longo DL, Chabner BA, eds. *Cancer Chemotherapy and Biological Response Modifiers Annual 13*. Amsterdam: Elsevier; 1992, 404-439.
107. Fried MW, Korenman JC, Di Bisceglie AM, Park Y, Waggoner JG, Mitsuya H, Hartman NR, **Yarchoan R**, Broder S, Hoofnagle JH. A pilot study of 2',3'-dideoxyinosine for the treatment of chronic hepatitis B. *Hepatology*. 1992; 16: 861-864.
108. Schacter LP, Rozencweig M, Beltangady M, Allan JD, Canetta R, Cooley TP, Dolin R, Kelley S, Lambert J, Liebman HA, Messina M, Nicaise C, Seidlin M, Valentine FT, **Yarchoan R**, Smaldone LF. Effects of therapy with didanosine on hematologic parameters in patients with advanced HIV disease. *Blood*. 1992; 80: 2969-2976.
109. Shirasaka T, **Yarchoan R**, O'Brien MC, Husson RN, Anderson BD, Kojima E, Broder S, Mitsuya H. Changes in drug-sensitivity of human immunodeficiency

**Robert Yarchoan, M.D.**

**Bibliography**

- virus type 1 during therapy with azidothymidine, dideoxycytidine, or dideoxyinosine: an *in vitro* comparative study. *Proc Natl Acad Sci USA*. 1993; 90: 562-566.
110. Zurlo JJ, O'Neill D, Polis MA, Manischewitz J, **Yarchoan R**, Baseler M, Lane HC, Masur H. The lack of clinical utility of cytomegalovirus (CMV) blood and urine cultures in patients with human immunodeficiency virus infection. *Ann Intern Med*. 1993; 118: 12-17.
111. McLaren C, Rozenzweig M, Beltangady M, Nicaise C, **Yarchoan R**, Dolin R, Allan JD, Cooley TP, Seidlin M, Smaldone LF. Longitudinal analysis of responses to oral didanosine therapy in patients with advanced HIV-infection who had received prior zidovudine therapy. *Clinical Infectious Dis*. 1993; 16 (Suppl 1): S32-S39.
112. Perno CF, **Yarchoan R**. Culture of human immunodeficiency virus in monocytes and macrophages. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. *Current Protocols in Immunology*. New York: John Wiley and Sons. 1993; 12 (Supplement 5).4.1-11
113. Pluda JM, Feigal E, Parkinson DR, **Yarchoan R**. Non-cytotoxic therapeutic approaches to the treatment of HIV-associated Kaposi's sarcoma. *Oncology*. 7(12):25-33, 1993.
114. Ahluwalia G, Cooney DA, Hartman NR, Mitsuya H, **Yarchoan R**, Fridland A, Broder S, Johns DG. Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine. *Drug Metabolism and Disposition*. 1993; 21 (2): 369-376.
115. Pluda JM, Brawley OW, **Yarchoan R**, Curt GA, Broder S. Neoplasms associated with AIDS. In: Calabresi P, Shein RS, eds. *Medical Oncology: The Basic Principles and Clinical Management of Cancer*. Elmsford, NY: Peragamon. 1993; 1173-1201.
116. Pluda JM, Venzon DJ, Tosato G, Lietzau J, Wyvill K, Nelson DL, Jaffe ES, Karp JE, Broder S, **Yarchoan R**. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. *J Clin Oncol*. 1993; 11(6): 1099-1107.
117. **Yarchoan R**, Mitsuya H, Broder S. Challenges in the therapy of HIV infection. *Immunology Today* 1993; 14(6): 303-309 and *Trends in Pharmacological Sciences* 1993; 14(5): 196-202 (Published by Elsevier, Inc. as part of a joint issue in both *Immunology Today* and *TiPS*).
118. **Yarchoan R**, Mitsuya H, Broder S. Antiretroviral approaches to the therapy of AIDS and related disorders. In: Levy J, Neu HC, Weiss R, eds. *Focus on HIV, 1992*. Churchill Livingstone, London: 1993; 297-314.
119. Clerici M, **Yarchoan R**, Blatt S, Hendrix CW, Ammann AJ, Broder S, Shearer GM. Effect of recombinant CD4-IgG on in vitro T helper cell function: data from a phase I/II study of patients with AIDS. *J Infectious Dis*. 1993; 168 (4): 1012-1016.

**Robert Yarchoan, M.D.**

**Bibliography**

120. Pluda JM, Shay LE, Foli A, Tannenbaum S, Cohen PJ, Christian MC, Adamo D, Broder S, **Yarchoan R**. Administration of pentosan polysulfate to patients with HIV-associated Kaposi's sarcoma. *J Natl Cancer Inst.* 1993; 85 (19): 1585-1592.
121. Nguyen B-Y, Landucci DL, Cunnion RE, **Yarchoan R**, Walker RE. Hyperdynamic shock, without features of anaphylaxis and without detectable tumor necrosis factor, caused by trimethoprim-sulfamethoxazole. *Clinical Infectious Diseases*, 1993; 17 (5): 885-887.
122. Nguyen B-YT, Sahy LE, Wyvill KM, Pluda JM, Brawley O, Cohen RB, Whitcup SM, Venzon DJ, Broder S, **Yarchoan R**. A pilot study of sequential therapy with zidovudine plus acyclovir, ddI, and ddC in patients with severe human immunodeficiency virus infection. *J Infect Dis.* 1993; 168 (4): 810-817.
123. **Yarchoan R**, Lietzau JA, Nguyen B-Y, Brawley OW, Pluda JM, Saville MW, Wyvill KM, Steinberg SM, Agbaria R, Mitsuya H, Broder S. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. *J Infect Dis.* 1994; 169 (1): 9-17.
124. Mitsuya H, **Yarchoan R**. Development of antiretroviral therapy for AIDS and related disorders. In: Broder S, Merigan TC Jr., Bolognesi D, eds. *Textbook of AIDS Medicine*. Williams and Wilkins, Baltimore. 1994; 721-742.
125. Kojima E, Shirasaka T, Anderson B, Choekijichia S, Sei S, **Yarchoan R**, Mitsuya H. Monitoring the activity of antiviral therapy for HIV infection using a polymerase chain reaction method coupled with reverse transcription. *AIDS* 1994; 7 (suppl 2): S101-106.
126. Figg WD, Yeh HJC, Thibault A, Pluda JM, Itoh F, **Yarchoan R**, Cooper MR. An assay of the antiangiogenic compound, TNP-470, and one of its metabolites, AGM-1883, by reversed-phase, high performance liquid chromatography in plasma. *J Chromatogr.* 1994; 652: 187-94.
127. Sei S, Kleiner DE, Kopp JB, Chandra R, Klotman PE, **Yarchoan R**, Pizzo PA, Mitsuya H. Quantitative analysis of viral burden in various tissues from adults and children with symptomatic HIV-1 infection assessed by polymerase chain reaction. *J Infect Dis.* 1994; 170 (2): 325-33.
128. Saville MW, Taga K, Foli A, Broder S, Tosato G, **Yarchoan R**. Interleukin-10 suppresses HIV-1 replication in cells of the monocyte/macrophage lineage. *Blood.* 1994; 83 (12): 3591-9.
129. Browning PJ, Sechler JMG, Kaplan M, Washington RH, Gendelman R, **Yarchoan R**, Ensoli B, Gallo RC. Identification and culture of Kaposi's sarcoma-like spindle cells from the peripheral blood of HIV-1-infected individuals and normal controls. *Blood.* 1994; 84 (8): 2711-20.
130. Anderson BD, Shirasaka T, Kojima E, **Yarchoan R**, Mitsuya H. Identification of drug-related genotype changes in HIV-1 from serum using the selective polymerase chain reaction. *Antiviral Research* 1994; 25: 245-58.
131. Pluda JM, Saville MW, Foli A, Broder S, **Yarchoan R**. The pathogenesis of HIV-associated Kaposi's sarcoma. In: Greenspan JS and Greenspan D, eds. *Oral manifestations of HIV infection: Proceedings of the Second International Workshop*. Quintessence, Carol Stream IL. 1995; 200-4.

## Robert Yarchoan, M.D.

### Bibliography

132. Shirasaka T, Kavlick MF, Ueno T, Gao W-Y, Kojima E, Alcaide ML, Choekijchai S, Roy BM, Arnold E, **Yarchoan R**, Mitsuya H. Emergence of human immunodeficiency virus type-1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. *Proc Natl Acad Sci, USA*. 1995; 92: 2398-2402.
133. Blauvelt A, Clerici M, Lucey DR, Steinberg S, **Yarchoan R**, Walker R, Shearer GM, Katz SI. Functional studies of epidermal Langerhans cells and blood monocytes in human immunodeficiency virus-infected individuals. *J Immunol*. 1995; 154 (7): 3506-15.
134. Nguyen B-Y, **Yarchoan R**, Wyvill KM, Venzon DJ, Pluda JM, Mitsuya H, Broder S. Five year follow-up of a phase I study of didanosine (ddI) in patients with advanced HIV infection. *J Infect Dis*. 1995; 171 (5): 1180-9.
135. Kojima E, Shirasaka T, Anderson BD, Choekijchai S, Steinberg SM, Broder S, **Yarchoan R**, Mitsuya H. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. *J Infect Dis*. 1995; 171 (5): 1152-7.
136. Foli A, Saville MW, Baseler MW, **Yarchoan R**. Effects of the Th<sub>1</sub> and Th<sub>2</sub> stimulatory cytokines interleukin-12 and interleukin-4 on human immunodeficiency virus replication. *Blood* 1995; 85 (8): 2114-23.
137. Yang Y, Bailey J, Vacchio MS, **Yarchoan R**, Ashwell JD. Retinoic acid inhibition of ex vivo HIV-associated apoptosis of peripheral blood cells. *Proc Natl Acad Sci, USA*. 1995; 92 (7): 3051-5.
138. Adamson PC, Bailey J, Pluda JM, Poplack DG, Bauza S, Murphy RF, **Yarchoan R**, Balis FM. The pharmacokinetics of all-*trans*-retinoic acid administered on an intermittent schedule. *J Clin Oncol*. 1995; 13 (5): 1238-41.
139. Pluda JM, Cooley TP, Montaner JSG, Shay LE, Reinhalter NE, Warthan SN, Ruedy J, Hirst HM, Vicary CA, Quinn JB, Yuen GJ, Wainberg MA, Rubin M, **Yarchoan R**. A phase I/II study of 2'-deoxy-3'-thiacytidine (3TC) in patients with advanced human immunodeficiency virus infection. *J Infect Dis*. 1995; 171 (6): 1438-47.
140. Saville MW, **Yarchoan R**. Antiretroviral therapy of HIV infection. In: Rich RR, Shearer WT, Strober W, Fleisher TA, Schwartz BD, eds. *Clinical Immunology, Principles and Practice.*, Mosby Year Book, St. Louis. 1995; 751-63.
141. Davis DA, Branca AA, Pallenberg AJ, Marchner TM, Patt LM, Chatlynne LG, Humphrey RW, **Yarchoan R**, Levine RL. Inhibition of human immunodeficiency virus-1 protease and human immunodeficiency virus-1 replication by bathocuproine disulfonic acid Cu<sup>1+</sup>. *Arch Biochem Biophys*. 1995; 322 (1): 127-34.
142. Bailey J, Pluda JM, Foli A, Saville MW, Bauza S, Adamson PC, Murphy RF, Cohen RB, Broder S, **Yarchoan R**. A phase I/II study of all-*trans*-retinoic acid alone and in combination with interferon-alpha in patients with epidemic Kaposi's sarcoma. *J Clin Oncol*. 1995; 13 (8): 1966-74.
143. Kavlick MF, Shirasaka T, Pluda J, Hui F, **Yarchoan R**, Mitsuya H. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving therapy

## Robert Yarchoan, M.D.

### Bibliography

- with (-)-2',3'-dideoxy-3'-thiacytidine (3TC). *Antiviral Research*. 1995; 28: 133-46.
144. Gu Z, Salomon H, Cherrington JM, Mulato AS, Chen MS, **Yarchoan R**, Foli A, Sogocio KM, Wainberg MA. The K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes resistance to 9-(2-phosphonylmethoxyethyl)adenine. *Antimicrob Agents Chemother*. 1995; 39 (8): 1888-91.
145. Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey R, Feigal E, Steinberg SM, Broder S, **Yarchoan R**. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. *Lancet* 1995; 346: 26-8.
146. Nguyen B-Y, **Yarchoan R**. Anti-AIDS Drugs. In: Chabner BA, Collins JM, eds. *Cancer Chemotherapy: Principles and Practice*. J.B. Lippincott Co., Philadelphia, Pa. 1996; 493-508.
147. **Yarchoan R** and Broder S. Treatment of HIV infection and AIDS. In: Bennett JC, Plum F, eds. *Cecil Textbook of Medicine, Twentieth Edition*. WB Saunders, Philadelphia, Pa. 1996; 1880-8.
148. Humphrey RW, O'Brien TR, Newcomb FM, Nishihara H, Wyvill KM, Ramos GA, Saville MW, Goedert JJ, Straus SE, **Yarchoan R**. Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells (PBMCs): Association with KS and persistence in patients receiving anti-herpes drugs. *Blood* 1996; 88: 297-301.
149. Lush RM, Nguyen B-Y, Cundy KC, Bauza S, Sogocio T, Stevens J, Piscitelli SC, Venzon DJ, **Yarchoan R**, Figg WD. The pharmacokinetics of (S)-9-[2-(phosphonylmethoxy)ethyl]adenine (PMEA) and zidovudine (AZT) when administered in combination. *J Applied Therapeutics* 1996; 1: 13-18.
150. Karp JE, Pluda JM, **Yarchoan R**. AIDS-Related KS: A template for the translation of molecular pathogenesis into targeted therapeutic approaches. *Hemato. Oncol Clinics of N America*. 1996; 10: 1031-50.
151. Stefanová I, Saville MW, Peters C, Cleghorn FR, Schwartz D, Venzon DJ, Weinhold KJ, Jack N, Bartolomew C, Blattnew WA, **Yarchoan R**, Bolen JB, Horak ID. HIV infection induced posttranslational modification of T cell signaling molecules associated with disease progression. *J Clin Invest*. 1996; 98 (6): 1290-7.
152. Foli A, Sogocio KM, Anderson B, Kavlick M, Saville MW, Wainberg MA, Gu Z, Cherrington JM, Mitsuya H, **Yarchoan R**. *In vitro* selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9[2-(phosphonomethoxy)ethyl]adenine (PMEA). *Antiviral Res*. 1996; 32: 91-8.
153. Brouwers P, Hendricks M, Lietzau J, Mitsuya H, Pluda JM, Broder S, **Yarchoan R**. Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: A comparison of simultaneous and alternating administration. *AIDS* 1997; 11 (1): 59-66.
154. Welles L, **Yarchoan R**. Therapy of HIV-1 infection with antiretroviral nucleosides. In: Mitsuya H, ed. *Anti-HIV Nucleosides*, R.G. Landes Co., Georgetown TX. 1997; 51-99.

**Robert Yarchoan, M.D.**

**Bibliography**

155. Figg WD, Pluda JM, Lush RM, Saville MW, Wyvill K, Reed E, **Yarchoan R**. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. *Pharmacotherapy*. 1997; 17(1): 91-7.
156. Davis DA, Humphrey RW, Newcomb FM, O'Brien TR, Goedert JJ, Straus SE, **Yarchoan R**. Detection of serum antibodies to a Kaposi's sarcoma associate herpesvirus-specific peptide. *J Infect Dis*. 1997; 175 (5): 1071-9.
157. Humphrey RW, Ohagen Å, Davis DA, Fukazawa T, Hayashi H, Höglund S, Mitsuya H, **Yarchoan R**. Removal of HIV-1 protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology. *Antimicrob Agents Chemother*. 1997; 41 (5): 1017-23.
158. Foli A, Saville MW, May LT, Webb DSA, **Yarchoan R**. Effects of human immunodeficiency virus and colony stimulating factors on the production of interleukin-6 and tumor necrosis factor- $\alpha$  by monocyte/macrophages. *AIDS Res and Human Retroviruses* 1997; 13 (10): 829-39.
159. Blauvelt A, Asada H, Saville MW, Klaus-Kovtun V, Altman DJ, **Yarchoan R**, Katz SI. Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways. *J Clin Invest*. 1997; 100 (8): 2043-2053.
160. Davis DA, Newcomb FM, Starke DW, Ott D, Mיעyal JJ, **Yarchoan R**. Thioltransferase (glutaredoxin) is detected within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease *in vitro*. *J Biol Chem*. 1997; 272 (41): 25935-40.
161. Humphrey RW, Davis DA, Newcomb FM, **Yarchoan R**. Human herpesvirus 8 (HHV-8) in the pathogenesis of Kaposi's sarcoma and other diseases. *Leukemia and Lymphoma*. 1998; 28: 255-64.
162. Kavlick MF, Wyvill K, **Yarchoan R**, Mitsuya H. Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral therapy. *J Infect Dis*. 1998; 98 (5): 1506-13.
163. Nguyen B-Y, Clerici M, Vanzon DJ, Bauza S, Murphy WJ, Longo DL, Baseler M, Gesundheit N, Broder S, Shearer G, **Yarchoan R**. A pilot study of the immunologic effects of recombinant human growth hormone, recombinant insulin-like growth factor, and combination therapy in patients with HIV infection. *AIDS* 1998; 12 (8): 895-904
164. Little R, Pluda JM., Feigal E, **Yarchoan R**. The challenge of clinical trial design in AIDS-related Kaposi's sarcoma. *Oncology*. 1998; 12 (6): 871-883.
165. Perno C-F, Newcomb FM, Davis DA, Aquaro S, Humphrey RW, Caliò R, **Yarchoan R**. Relative potency of protease inhibitors in monocyte/macrophages acutely and chronically infected with human immunodeficiency virus. *J Infect Dis*. 1998; 178 (2): 413-22.
166. Welles L, **Yarchoan R**. Human immunodeficiency virus. In: VL Yu, TC Merigan, and SL Barriere, eds., *Antimicrobial Therapy and Vaccines*. Williams and Wilkins, Baltimore, 1998; 1264-87.
167. Welles L, Saville MW, Lietzau J, Pluda JM, Wyvill KM, Feuerstein I, Figg WD, Lush R, Odom J, Wilson WH, Fajardo MT, Humphrey RW, Feigal E, Tuck D,

## Robert Yarchoan, M.D.

### Bibliography

- Steinberg SM, Broder S, **Yarchoan R**. A phase II trial with dose titration of paclitaxel for the therapy of HIV-associated Kaposi's sarcoma. *J Clin Oncol*. 1998; 16 (3): 1112-21.
168. Williams SB, Sano M, Smith N, Horne M, **Yarchoan R**, Wyvill K, Zeichner S, Taylor P, Knudson T, Gralnick HR. Glycocalicin levels in the plasma of HIV+ patients: An indicator of platelet turnover. *J Lab and Clinical Med*. 1998; 132 (4): 303-7.
169. Serchuk L, Welles L, **Yarchoan R**. Antiretroviral treatment for human immunodeficiency virus infection. In: Merigan TC Jr., Bartlett J.G., Bolognesi D, eds. *Textbook of AIDS Medicine, Second Edition*. Williams and Wilkins, Baltimore. 1998; 780-806.
170. Zeichner S, Read Jennifer, Willoughby A, **Yarchoan R**. Future challenges of pediatric HIV care. In: Zeichner SL and Read JS, eds. *Handbook of Pediatric Care*. Lippincott-Raven Publishers, Philadelphia. 1999; 608-14.
171. Humphrey RW, Wyvill KM, Nguyen B-Y, Shay LE, Kohler DR, Steinberg SM, Ueno T, Fukasawa T, Shintani M, Hayashi H, Mitsuya H, **Yarchoan R**. A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection. *Antiviral Research*, 1999; 41: 21-33.
172. **Yarchoan, R**. Therapy for Kaposi's sarcoma: Recent advances and experimental approaches. *J AIDS and Human Retrovirology*. 1999; 21 (Suppl 1): 66-73.
173. Monini P, Colombini S, Stürzl M, Goletti D, Cafaro A, Sgadari C, Buttò S, Franco M, Leone P, Fais S, Leone P, Melucci-Vigo G, Chiozzini C, Carlini F, Ascherl G, Cornali E, Zietz C, Ramazzotti E, Ensoli F, Andreoni M, Pezzotti P, Rezza G, **Yarchoan R**, Gallo RC, Ensoli B. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. *Blood*. 1999; 93(12): 4044-58.
174. Pinto LA, Berzofsky JA, Fowke KR, Little RF, Merced-Galindez F, Humphrey R, Ahlers J, Dunlop N, Cohen RB, Steinberg SM, Nara P, Shearer GM, **Yarchoan R**. HIV-Specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected persons. *AIDS* 1999; 13 (15): 2003-12.
175. Grossman Z, Polis M, Feinberg MB, Grossman Z, Levi Itschak, Jankelevich S, **Yarchoan R**, Boon J, de Wolf F, Lange JMA, Goudsmit J, Dimitrov DS, Paul WE. Ongoing HIV replication under HAART. *Nature Medicine* 1999; 5(10): 1099-1104.
176. Jones KD, Aoki Y, Chang Y, Moore PS, **Yarchoan R**, Tosato G. Involvement of IL-10 and viral IL-6 in the spontaneous growth of Kaposi's sarcoma-infected body cavity lymphoma cells. *Blood* 1999; 94 (8): 2871-9.
177. Davis DA, Yusa K, Gillim LA, Newcomb FM, Mitsuya H, **Yarchoan R**. The conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions. *J Virol*. 1999; 73 (2): 1156-64.
178. **Yarchoan R** and Broder S. Treatment of HIV infection and AIDS. In: Bennett JC, Goldman L, eds. *Cecil Textbook of Medicine, Twenty First Edition*. WB Saunders, Philadelphia, 1999; 1933-42.

## Robert Yarchoan, M.D.

### Bibliography

179. Little R, **Yarchoan R**. Considerations in the management of HIV infection in patients undergoing antineoplastic chemotherapy. In: EG Feigal, AM Levine, RJ Bigger, eds. *AIDS-Related Cancers and their Treatment*. Marcel Dekker, Inc., New York. 2000; 281-330.
180. Davis DA, Newcomb FM, Moskovitz J, Wingfield PT, Stahl SJ, Kaufman J, Fales HM, Levine RL, **Yarchoan R**. HIV-2 protease is inactivated following oxidation at the dimer interface and activity can be partially restored with methionine sulfoxide reductase. *Biochem Journal* 2000; 346 (2): 305-311.
181. Lehrnbecher T, Foster CB, Zhu S, Vanzon D, Steinberg SM, Wyvill K, Metcalf JA, Cohen SS, Kovacs J, **Yarchoan R**, Blauvelt A, Chanock SJ. Variant genotypes of *FcγRIIIA* influence the development of Kaposi's sarcoma in HIV-infected men. *Blood*. 2000; 95 (7): 2386-2390.
182. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, Newcomb FM, Tosato G, Feigal E, Steinberg SM, Whitby D, Goedert JJ, **Yarchoan R**. Activity of thalidomide in AIDS-related Kaposi's sarcoma. *J Clin Oncol*. 2000; 18(13): 2593-2602.
183. Sgadari C, Toschi E, Palladino C, Barillari G, Carlei D, Cereseto A, Ciccolella C, **Yarchoan R**, Monini P, Stürzl M, Ensoli B. Mechanism of paclitaxel activity in Kaposi's sarcoma. *J Immunol*. 2000; 165(1): 509-17.
184. Aoki Y, **Yarchoan R**, Braun J, Iwamoto A, Tosato G. Viral and cellular cytokines in AIDS-related lymphomatous effusions. *Blood*. 2000; 96(4): 1599-1601.
185. Little RF, **Yarchoan R**, Wilson WH. Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy. *Current Opinions in Oncology*. 2000; 12(5): 438-44.
186. Foster CB, Lehrnbecher T, Samuels S, Stein S, Mol F, Metcalf J, Wyvill K, Steinberg SM, Kovacs J, Blauvelt A, **Yarchoan R**, Chanock SJ. An *IL6* promoter polymorphism is associated with lifetime risk of developing Kaposi's sarcoma (KS) in HIV-infected men. *Blood*. 2000; 96(7): 2562-7.
187. Cocchi F, DeVico AL, **Yarchoan R**, Redfield R, Cleghorn F, Blattner WA, Garzino-Demo A, Colombini-Hatch S, Margolis D, Gallo RC. Higher macrophage inflammatory protein (MIP)-1 $\alpha$  and MIP-1 $\beta$  levels from CD8<sup>+</sup> T cells are associated with asymptomatic HIV-1 infection. *Proc Natl Acad Sci. USA* 2000; 97(25): 13812-7.
188. **Yarchoan R** and Little R. AIDS-Related Malignancies. In: DeVita VT, Hellman S, Rosenberg SA. *Cancer. Principles and Practice of Oncology. Sixth Edition*. Lippincott Williams and Wilkins, Philadelphia, 2001; 2575-2597.
189. Dai F, Kelley JA, Zhang H, Malinowski N, Kavlick MF, Lietzau J, Welles L, **Yarchoan R**, Ford H. 2'-beta-fluoro-2',3'-dideoxyadenosine-5'-triphosphate, the active metabolite of a new anti-HIV drug, in human lymphocytes. *Anal Biochem*. 2001; 288: 52-61.
190. Aoki Y, **Yarchoan R**, Wyvill K, Okamoto S-I, Little RF, Tosato G. Detection of viral interleukin-6 in Kaposi's sarcoma-associated herpesvirus-linked disorders. *Blood*. 2001; 97: 2173-6.
191. Zoetewij JP, Moses AV, Rinderknecht AS, Davis DA, Overwijk WW, **Yarchoan R**, Orenstein JM, Blauvelt A. Targeted inhibition of calcineurin

## Robert Yarchoan, M.D.

### Bibliography

- signaling blocks calcium-dependent reactivation of Kaposi's sarcoma-associated herpesvirus. *Blood* 2001; 97: 2374-80.
192. Paulose-Murphy M, Nguyen-Khoi H, Xiang C, Chen Y, Gillim L, **Yarchoan R**, Meltzer P, Bittner M, Trent J, Zeichner S. The transcription program of herpesvirus-8 (Kaposi's sarcoma associated herpesvirus). *J Virol.* 2001; 75(10): 4843-53.
193. Fry TJ, Connick E, Falloon J, Lederman MM, Liewehr DJ, Spritzler J, Steinberg SM, Wood LV, **Yarchoan R**, Zuckerman J, Landry A, Mackall CL. A potential role for IL-7 in T-cell homeostasis. *Blood.* 2001; 97 (10): 2983-90.
194. Davis DA, Rinderknecht AS, Zoetewij JP, Aoki Y, Read-Connole EL, Tosato G, Blauvelt A, **Yarchoan R**. Hypoxia induces lytic replication of Kaposi's sarcoma-associated herpesvirus. *Blood.* 2001; 97 (10): 3244-50.
195. Chougnet C, Jankelevich S, Fowke K, Liewehr D, Steinberg SM, Mueller BU, Pizzo PA, **Yarchoan R**, Shearer GM. Long-term protease inhibitor-containing therapy results in limited improvements in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS. *J Infect Dis.* 2001; 184: 201-5.
196. Blazevic V, Jankelevich S, Steinberg SM, Jacobsen F, **Yarchoan R**, Shearer GM. Highly active antiretroviral therapy in HIV-1 infected children: analysis of cellular immune responses. *Clin Diagnostic Lab Immunol.* 2001; 8 (5): 943-8.
197. Polis MA, Sidorov IA, Yoder C, Jankelevich S, Metcalf J, Mueller BU, Dimitrov MA, Pizzo P, **Yarchoan R**, Dimitrov DS. Reduction in plasma HIV-1 RNA by one week following initiation of antiretroviral treatment correlates with longer-term efficacy. *Lancet.* 2001; 358: 1960-5.
198. Jankelevich S, Mueller BU, Mackall CL, Smith S, Zwierski S, Wood LV, Zeichner S, Serchuck L, Steinberg SM, Nelson RP, Sleasman JW, Nguyen B-Y, Pizzo PA, **Yarchoan R**. Long-term virologic and immunologic responses in human immunodeficiency virus type 1 (HIV-1)-infected children treated with indinavir, zidovudine, and lamivudine. *J Infect Dis.* 2001; 183: 1116-20.
199. Zoetewij JP, Rinderknecht AS, Davis DA, **Yarchoan R**, Blauvelt A. Minimal reactivation of Kaposi's sarcoma-associated herpesvirus by corticosteroids in latently infected B cell lines. *J Med Virol.*, 2002; 66(3): 378-83.
200. Davis DA, Read-Connole E, Pearson K, Fales HM, Newcomb FM, Moskovitz J, **Yarchoan R**. Oxidative modifications of a potent HIV-1 protease inhibitor: A potential mechanism for altered activity in monocytes/macrophages. *Antimicrobial Agents Chemotherapy*, 2002; 46(2): 402-8.
201. Davis DA, Newcomb FM, Moskovitz J, Fales HM, Levine RL, **Yarchoan R**. Inactivation of HIV-2 protease through methionine oxidation and its restoration by methionine sulfoxide reductase. In: Seis H and Lacker L, Eds. *Protein Sensors of Reactive Oxygen Species: Thiol Enzymes and proteins. Part 2. Methods in Enzymology.* Academic press, Inc., Orlando, FL, 2002; 348, 249-59.
202. Valentin A, Rosati M, Patenaude DJ, Hatzakis A, Kostrikis LG, Lazanas M, Wyvill KM, **Yarchoan R**, Pavlakis G. Persistent HIV-1 infection of natural killer cells receiving highly active anti-retroviral therapy. *Proc Nat Acad Sci. USA.* 2002; 99(10): 7015-20.

**Robert Yarchoan, M.D.**

**Bibliography**

203. Kumar PP, Little RF, **Yarchoan R**. Update on Kaposi's sarcoma, a gammaherpesvirus-induced malignancy. *Current Infectious Disease Reports*, 2003; 5: 85-92.
204. Little RF and **Yarchoan R**. Issues in the management of HIV infection in patients undergoing anti-neoplastic chemotherapy. *Current Treatment Options in Infectious Diseases*. 2003; 5(2): 119-126.
205. Little RF and **Yarchoan R**. Treatment of gammaherpesvirus-related neoplastic disorders in the immunosuppressed host. *Seminars in Hematology*. 2003; 40(2): 163-71.
206. Davis DA, Brown CA, Newcomb FM, Boja ES, Fales HM, Kaufman J, Stahl SJ, Wingfield P, **Yarchoan R**. Reversible oxidative modification as a mechanism of regulating retroviral protease dimerization and activation. *J Virol*. 2003; 77(5): 3319-25.
207. Bryant-Greenwood PK, Sorbara L, Filie AC, Little R, **Yarchoan R**, Wilson W, Raffeld M, Abati A. Infection of mesothelial cells with HHV-8 in HIV+ Patients with Kaposi's sarcoma, Castleman's disease, and recurrent pleural effusions. *Modern Pathology*. 2003; 16(2): 145-53.
208. Yao L, Salvucci O, Cardones AR, Hwang ST, Aoki Y, Sierra MDLL, Sajewicz A, Pittaluga S, **Yarchoan R**, Tosato G. Selective expression of stromal-derived factor-1 in the capillary vascular endothelium plays a role in Kaposi's sarcoma pathogenesis. *Blood*. 2003; 102(12): 3900-5.
209. Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, Franchini G, Guterrez M, Raffeld M, Jaffe ES, Shearer G, **Yarchoan R**, Wilson WH. Highly effective treatment of acquired immunodeficiency syndrome related lymphoma with dose-adjusted EPOCH: Impact of antiretroviral therapy suspension and tumor biology. *Blood*. 2003; 101(12): 4653-9.
210. Little RF, **Yarchoan R**. The use of antiretroviral therapy in patients undergoing treatment for HIV-related neoplastic disease. *Research Initiative/Treatment Action* 2003; 9(1): 19-25.
211. Villalba S, Salvucci O, Aoki Y, Sierre ML, Gupta G, Davis DA, Wyvill K, Little R, **Yarchoan R**, Tosato G. Serum inactivation contributes to the failure of stromal-derived factor-1 to block HIV-I infection in vivo. *J Leukocyte Biol*. 2003; 74 (5): 880-8.
212. Smith SM, Pentlicky S, Klase Z, Singh M, Neuvent C, Lu C-Y, Reitz MS, **Yarchoan R**, Marx PA, Jeang K-T. An *in vivo* replication-important function in the second coding exon of Tat is constrained against mutation in spite of CTL selection. *J Biol Chem.*, 2003; 278 (45): 44816-25.
213. Little RF, Merced-Galindez F, Staskus K, Whitby D, Aoki Y, Humphrey R, Pluda JM, Marshall V, Walters M, Welles L, Rodriguez-Chavez IR, Pittaluga S, Tosato G, **Yarchoan R**. A pilot study of cidofovir in patients with Kaposi's sarcoma. *J Infect Dis*. 2003; 187(1): 149-53.
214. Haque M, Davis DA, Wang V, Widmer I, **Yarchoan R**. KSHV/HHV-8 contains hypoxia response elements: Relevance to lytic induction by hypoxia. *J Virol*. 2003; 77(12): 6761-8.
215. Hassan M, Hattery D, Vogel A, Chernomordik V, Aleman K, Little R, Demos S, **Yarchoan R**, Gandjbakhche AH. Noninvasive infrared imaging for quantitative

## Robert Yarchoan, M.D.

### Bibliography

- assessment of tumor vasculature and response to therapy. *Conf Proc IEEE Eng Med Biol Soc.* 2004; 2: 1200-2.
216. Sierra MDLL, Yang F, Narazaki M, Salvucci O, Davis DA, **Yarchoan R**, Zhang HH, Fales H, Tosato G. Differential processing of stromal-derived factor-1  $\alpha$  and  $\beta$  explains functional diversity. *Blood.* 2004; 103(7): 2452-9.
  217. Hassan M, Little RF, Vogel A, Aleman K, Wyvill K, **Yarchoan R**, Gandjbakhche AH. Quantitative assessment of tumor vasculature and response to therapy in Kaposi's sarcoma using functional noninvasive imaging. *Technol Cancer Res Treat* 2004; 3(5): 451-8.
  218. Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV, Zwierski S, **Yarchoan R**, Zeichner S. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. *Pediatrics.* 2004; 114(2): e235-42.
  219. Gandjbakhche A, Vogel A, Amyot F, Chernomordik V, Hassan M, Demos S, Aleman K, Little R, **Yarchoan R**. Noninvasive multimodality imaging techniques to assess Kaposi's sarcoma. *Conf Proc IEEE Eng Med Biol Soc.* 2005; 1: 694-6.
  220. **Yarchoan R**, Little RF. AIDS-related malignancies. In: DeVita VT Jr., Hellman S, and Rosenberg SA, Eds., *Cancer: Principles and Practice of Oncology, 7<sup>th</sup> Edition*. Lippincott Williams and Wilkins, Philadelphia, 2005; 2247-2262.
  221. Davis DA, Singer K, De La Luz Serra M, Narazaki M, Yang F, Fales H, **Yarchoan R**, Tosato G. Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1 $\alpha$  in the circulation. *Blood.* 2005; 105(12): 4561-8.
  222. Wang V, Davis DA, Haque M, Huang LE, **Yarchoan R**. Differential gene up-regulation by hypoxia-inducible factor 1 $\alpha$  (HIF-1 $\alpha$ ) and hypoxia inducible factor 2 $\alpha$  (HIF-2 $\alpha$ ) in HEK293T Cells. *Cancer Research.* 2005; 65(8): 3299-3306.
  223. **Yarchoan R**, Tosato G, Little RF. Therapy Insight: AIDS-related malignancies - the influence of antiviral therapy on pathogenesis and management. *Nature Clinical Practice Oncology.* 2005; 2(8): 406-15.
  224. Vogel A, Dasgeb B, Hassan M, Chernomordik V, Tao Y, Demos SG, Wyvill K, Aleman K, Little R, **Yarchoan R**, Gandjbakhche AH. Using Quantitative Imaging Techniques to Assess Vascularity in AIDS-Related Kaposi's Sarcoma. *Conf Proc IEEE Eng Med Biol Soc.* 2006;1:232-5.
  225. Tosato G, Little RF, **Yarchoan R**. EBV and KSHV-associated Malignancies. In: Young N, Gerson S, and High K, Eds., *Clinical Hematology*. Elsevier Inc., Philadelphia, 2006; 610-624.
  226. Semenova EA, Johnson AA, Marchand C, Davis DA, **Yarchoan R**, Pommier Y. Preferential inhibition of the magnesium-dependent trans transfer reaction of HIV-1 integrase by  $\alpha$ -hydroxytropolones. *Molecular Pharm.* 2006; 69(4): 1454-1460.
  227. Bernstein WB, Little RF, Wilson WH, **Yarchoan R**. Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy. *Internat J Heme.* 2006; 84 (1): 3-11.

## Robert Yarchoan, M.D.

### Bibliography

228. Hassan M, Chernomordik V, Vogel A, Hattery D, Gannot I, **Yarchoan R**, Gandjibakhche AH. Infrared imaging for tissue characterization and function. In: Bronzino, Ed., *The Biomedical Engineering Handbook, Third Edition*, CRC Press, Boca Raton, FL, 2006, 30-1 - 30-25.
229. Little RF, Pluda JM, Wyvill KM, Rodriguez-Chavez IR, Tosato G, Catanzaro AT, Steinberg SM, **Yarchoan R**. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi's sarcoma. *Blood*. 2006; 107(12): 4650-4657.
230. Haque M, Wang V, Davis DA, Zheng ZM, **Yarchoan R**. Genetic organization of the Kaposi's sarcoma-associated herpesvirus (KSHV) ORF34-37 gene cluster. *J Virol*. 2006; 80 (14): 7037-51.
231. Davis DA, Brown CA, Singer KE, Wang V, Kaufman J, Stahl SJ Wingfield P, Maeda K, Harada S, Yoshimura K, Kosalaraksa P, Mitsuya H, **Yarchoan R**. Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease. *Antiviral Research*. 2006; 72(2): 88-99.
232. Okazaki T, Terabe M, Catanzaro AT, Pendleton CD, **Yarchoan R**, Berzofsky JA. Possible therapeutic vaccine strategy against HIV escape from RT inhibitor studied in HLA-A2 transgenic mice. *J Virol*. 2006; 80(21):10645-51.
233. **Yarchoan, R**. Clinical Implications of Basic Research: Key role for a viral lytic gene in Kaposi's sarcoma. *New Engl J. Med.*, 2006; 355(13): 1383-1385.
234. Marshall V, Parks T, Bagni R, Wang CD, Samols MA, Hu J, Wyvill KM, Aleman K, Little RF, **Yarchoan R**, Renne R, Whitby D. Conservation of virally-encoded microRNA's in the Kaposi's sarcoma associated herpesvirus (KSHV) in primary effusion lymphoma cell lines and in patients with Kaposi's sarcoma or multicentric Castleman's disease. *J Infect Diseases* 2007; 195(5):645-59.
235. Hazra R, Jankelevich S, Mackall CL, Avila NA, Wolters P, Civitello L, Christensen BL, Jacobsen F, Steinberg SM, **Yarchoan R**. Immunologic, virologic, and neuropsychological responses in HIV-infected children receiving their first HAART regimen. *Viral Immunology*. 2007; 20(1): 131-41.
236. Davis DA, Singer KE, Reynolds IP, Haque M, **Yarchoan R**. Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in KSHV-infected cells. *Cancer Research*. 2007; 67(14): 7003-10.
237. Tang S, Zhao J, Storhoff JJ, Norris PJ, Little RF, **Yarchoan R**, Stramer SL, Patno T, Domanus M, Dhar A, Mirkin CA, Hewlett IK. Nanoparticle based biobarcode amplification assay (BCA) for sensitive and early detection of human immunodeficiency virus type 1 capsid (p24) antigen. *J. of Acquired Immunodeficiency Syndromes*. 2007; 46(2): 231-237.
238. Koh Y, Matsumi S, Das D, Amano M, Davis DA, Li J, Laschenko S, Baldrige A, Shioda T, **Yarchoan R**, Ghosh AK, Mitsuya H. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. *J. Biol. Chem*. 2007; 282(39): 28709-28720.
239. **Yarchoan R**, Pluda JM, Wyvill KM, Aleman K, Rodriguez-Chavez IR, Tosato G, Catanzaro AT, Steinberg SM, Little RF. Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: Rationale and preliminary evidence of clinical activity. *Critical Reviews in Immunology*. 2007; 27(5), 401-14.

**Robert Yarchoan, M.D.**

**Bibliography**

240. Little RF, Pittaluga S, **Yarchoan R**. Non-Hodgkin lymphoma. In: Dolin R, Masur H, Saag MS, Eds. *AIDS Therapy, 3rd Edition*. Churchill Livingstone/Elsevier, Philadelphia. 2007; 1031-1050.
241. **Yarchoan R**, Little RF. AIDS-related malignancies. In: DeVita VT Jr., Lawrence TS, and Rosenberg SA, Eds., *Cancer: Principles and Practice of Oncology, 8<sup>th</sup> Edition*. Lippincott Williams and Wilkins, Philadelphia. In press.
242. Vogel A, Chernomordik VV, Riley JD, Hasssan M, Amyot F, Dasgeb B, Demos SG, Pursley R, Little R, **Yarchoan R**, Tao Y, Gandijbakhche AH. Using noninvasive multispectral tissue imaging to quantitatively assess tissue vasculature. *J. of Biomedical Optics* 2007;12(5): 051604-17.
243. Little RF, Aleman K, Kumar P, Wyvill KM, Pluda JM, Read-Connole E, Wang V, Pittaluga S, Catanzaro AT, Steinberg SM, **Yarchoan R**. Phase II study of pegylated liposomal doxorubicin in combination with interleukin-12 for Kaposi's sarcoma. *Blood*. 2007; 110(13), 4165-71.
244. Morrow M, Valentin A, Little R, **Yarchoan R**, Pavlakis GN. A splenic marginal zone-like peripheral blood CD27<sup>+</sup> B220<sup>-</sup> population is preferentially depleted in HIV-1 infected individuals. *AIDS Research and Human Retroviruses*. 2008; In press.

## Robert Yarchoan, M.D.

### Bibliography

#### 245. Editorials, Letters to Editor

1. **Yarchoan R**, Little R. Optimizing combination therapy for Kaposi's sarcoma [Editorial]. *The Cancer Journal from Scientific American*. 1997; 3(3): 268-70.
2. **Yarchoan R**, Jaffe ES, Little R. Diagnosing central nervous system lymphomas: A step forward [Editorial]. *J. Natl. Cancer Inst.* 1998; 90 (5): 346-7.
3. **Yarchoan R** and Vella S. Clinical treatment: Overview. [Editorial review.] *AIDS 1999, A Year in Review*. *AIDS* 1999; 13 (suppl A): S175-6.
4. Aoki Y, Tosato G, Nambu Y, Iwamoto A, **Yarchoan R**. Detection of vascular endothelial growth factor in AIDS-related primary effusion lymphomas [Letter]. *Blood* 2000; 95(3): 1109-1110.
5. **Yarchoan R**. Commentary on "AIDS-related Kaposi's sarcoma: Current treatments, future trends." [Commentary] *Oncology*. 2000; 14(6): 887-8.
6. Carr A and **Yarchoan R**. Clinical treatment: Overview. [Editorial review.] *AIDS 2000, A Year in Review*. *AIDS*.2000; 14 (suppl 3): S187-8.
7. **Yarchoan R** and Little RF. Commentary on "AIDS malignancies in the era of highly active antiretroviral therapy." [Commentary]. *Oncology* 2002; 16(5): 669-70.
8. **Yarchoan R**, Davis DA, Rinderknecht A. "Development of Kaposi's sarcoma at the site of a biopsy." [Letter to editor]. *New Engl. J. Med.* 2002; 347 (10): 763-4.
9. **Yarchoan, R**. KSHV induces heme oxygenase: Another trick by a wily virus. [Editorial; Inside Blood] *Blood* 2004; 103(9): 3252-3.
10. Little RF and **Yarchoan R**. Poor specific T cell responses to human herpesvirus-8: A key to unleash Kaposi's sarcoma? [Editorial]. *J. Infect. Dis.* 2006; 194(8): 1030-1031.
11. **Yarchoan R** and Haque M. KSHV wages a two-front war on PECAM/CD31 [Editorial; Inside Blood]. *Blood* 2006; 108(6): 1790-91.

#### Edited Works

1. Volberding P and **Yarchoan R**, Eds. *The Optimal Management of Patients with HIV: Issues and Advances*. *AIDS*. 1999; 13 (suppl 1).
2. Harada S, Folks T, Buvé A, Padian N, Stott J, Hahn B, Vella S, **Yarchoan R**, Caraël M, and Des Jalais D, Eds. *AIDS 1999, A Year in Review*. *AIDS* 1999; 13 (suppl A).
3. Folks T, Wain-Hobson S, Rezza G, Padian N, Heeney JL, Hahn BH, Carr A, **Yarchoan R**, and Brown T, Eds. *AIDS 2000, A Year in Review*. *AIDS* 2000; 14 (suppl 3).

**Robert Yarchoan, M.D.**  
**Bibliography**

**U.S. Patents**

1. Nelson D, Biddison WE, Rubin L, Greene W, Leonard W, **Yarchoan R**. US patent 4,707,443 (Appl # 06/724,897): Soluble interleukin-2-receptor as a disease indicator and a method of assaying the same. November 17, 1987
2. Broder S, Mitsuya H, **Yarchoan R**. US patent 4,861,759 (Appl # 07/084,055): Antiviral compositions and methods. August 29, 1989.
3. Mitsuya H, Broder S, **Yarchoan R**. US patent 4,879,277 (Appl # 07/084,054): Antiviral compositions and methods. November 7, 1989.
4. **Yarchoan R**, Mitsuya H, Broder S. US patent 5,026,687 (Appl. # 07/460,490): Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds. June 25, 1991.
5. Mitsuya H, Broder S, **Yarchoan R**. US Patent 5,254,539 (Appl # 07/663,288): Method for treating HIV with 2',3'-dideoxyinosine. October 19, 1993.
6. **Yarchoan R**, Mitsuya H, Broder S. US patent 5,376,642 (Appl # 08/026,188): Treatment of retroviral induced dementia by administration of 2',3'-dideoxyinosine. December 27, 1994.
7. Mitsuya H, Broder S, **Yarchoan R**. (Appl # 08/056,043): US Patent 5,616,566: Method of inhibiting HIV replication with 2',3'-dideoxyadenosine. April 1, 1997.
8. **Yarchoan R**, Saville MW, Tosato G, Taga K. (Appl # 08/066,785). US Patent 5,665,345. Methods of inhibiting viral replication using IL-10. September 9, 1997.
9. **Yarchoan R**, Pluda JM, Wyvill KM, Lietzau J, Shearer GM, Feigal E, Tosato G, Little RF, Sherman ML. (Appl # 09/672,448) US Patent 6,423,308: Treatment of Kaposi's sarcoma with IL-12. July 23, 2002.
10. **Yarchoan R**, Pluda JM, Wyvill KM, Lietzau J, Shearer GM, Feigal E, Tosato G, Little RF, Sherman ML. (Appl # 09/672,448) US patent 6,509,321. Treatment of Kaposi's sarcoma with IL-12. January 21, 2003.